once-weekly administration of exenatide 2 mg. Both treatments were generally well tolerated; however, liraglutide treatment was associated with more gastrointestinal adverse events and discontinuations. Our ﬁ  ndings, in addition to diﬀ  erences in injection frequency and method of injection, will help to inform therapeutic decisions for the treatment of patients with type 2 diabetes.